# Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

> **NCT03283826** · PHASE1,PHASE2 · TERMINATED · sponsor: **Atara Biotherapeutics** · enrollment: 134 (actual)

## Conditions studied

- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** ATA188
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03283826
- **Lead sponsor:** Atara Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-19
- **Primary completion:** 2023-11-09
- **Final completion:** 2024-01-17
- **Target enrollment:** 134 (ACTUAL)
- **Why stopped:** Study was terminated as primary endpoint was not achieved
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283826, "Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03283826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*